Innoviva Inc

Stock Chart, Company Information, and Scan Results

$22.17(as of Mar 16, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Innoviva Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$22.17
Ticker SymbolINVA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees159
CountyUSA
Market Cap$1,659.9M
EBIDTA200.0M
10-Day Moving Average22.25
P/E Ratio6.96
20-Day Moving Average22.87
Forward P/E Ratio11.39
50-Day Moving Average21.37
Earnings per Share1.66
200-Day Moving Average20.12
Profit Margin139.06%
RSI48.87
Shares Outstanding74.8M
ATR0.64
52-Week High25.15
Volume562,453
52-Week Low16.52
Most Recent Support Level21.66
Book Value1,172.8M
Most Recent Resistance Level22.71
P/B Ratio1.61
Upper Keltner24.32
P/S Ratio4.55
Lower Keltner21.43
Debt-to-Equity Ratio24.32
Next Earnings Date05/13/2026
Cash Surplus501.2M
Next Ex-Dividend DateUnknown

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva Inc In Our Stock Scanner

As of Mar 17, 2026
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PE RatiosScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.